KRASG12C exhibits allele-specific biology in pancreatic cancer and targeting CD24 sensitizes KRASG12C-driven tumors to sotorasib treatment

被引：0
作者：
Wei, Yongkun
Liu, Minghui
Nguyen, Phuoc T.
Pan, Dean N.
Yao, Wantong
Ying, Haoqiang
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 02期
关键词：
D O I：
10.1158/1538-7445.PANCA2023-C097
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C097
引用
收藏
页数：2
相关论文
共 50 条
  • [31] XNW14010: A highly selective KRASG12C inhibitor with potent efficacy in animal model of pancreatic cancer
    Hu, Yonghan
    Li, Xin
    Huang, Bin
    Kong, Liang
    Le, Meijie
    Li, Yan
    Liu, Cungang
    Liu, Xiaojun
    Qian, Bin
    Qiang, Jing
    Shi, Qifeng
    Wang, Wengui
    Wu, Yuchuan
    Wu, Zhenwei
    Xu, Linfeng
    Zhao, Jinfeng
    [J]. CANCER RESEARCH, 2022, 82 (22) : 49 - 50
  • [32] Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
    Fell, Jay B.
    Fischer, John P.
    Baer, Brian R.
    Blake, James F.
    Bouhana, Karyn
    Briere, David M.
    Brown, Karin D.
    Burgess, Laurence E.
    Burns, Aaron C.
    Burkard, Michael R.
    Chiang, Harrah
    Chicarelli, Mark J.
    Cook, Adam W.
    Gaudino, John J.
    Hallin, Jill
    Hanson, Lauren
    Hartley, Dylan P.
    Hicken, Erik J.
    Hingorani, Gary P.
    Hinklin, Ronald J.
    Mejia, Macedonio J.
    Olson, Peter
    Otten, Jennifer N.
    Rhodes, Susan P.
    Rodriguez, Martha E.
    Savechenkov, Pavel
    Smith, Darin J.
    Sudhakar, Niranjan
    Sullivan, Francis X.
    Tang, Tony P.
    Vigers, Guy P.
    Wollenberg, Lance
    Christensen, James G.
    Marx, Matthew A.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (13) : 6679 - 6693
  • [33] HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2
    Ho, Cassandra S. L.
    Tuens, Alicia, I
    Schildhaus, Hans-Ulrich
    Wiesweg, Marcel
    Gruener, Barbara M.
    Hegedus, Balazs
    Schuler, Martin
    Schramm, Alexander
    Oeck, Sebastian
    [J]. EUROPEAN JOURNAL OF CANCER, 2021, 159 : 16 - 23
  • [34] Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the US
    Zhang, Peng
    Xu, Nong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Design, synthesis and biological evaluation of pyrrolopyrimidine urea derivatives as novel KRASG12C inhibitors for the treatment of cancer
    Shang, Yanguo
    Pang, Miaomiao
    Fu, Shengnan
    Fei, Wenjuan
    Chen, Boxuan
    Zhang, Yaoyao
    Wang, Jinxin
    Shen, Tao
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 289
  • [36] JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors
    Lorthiois, Edwige
    Gerspacher, Marc
    Beyer, Kim S.
    Vaupel, Andrea
    Leblanc, Catherine
    Stringer, Rowan
    Weiss, Andreas
    Wilcken, Rainer
    Guthy, Daniel A.
    Lingel, Andreas
    Bomio-Confaglia, Claudio
    Machauer, Rainer
    Rigollier, Pascal
    Ottl, Johannes
    Arz, Dorothee
    Bernet, Pascal
    Desjonqueres, Gaelle
    Dussauge, Solene
    Kazic-Legueux, Malika
    Lozac'h, Marie-Anne
    Mura, Christophe
    Sorge, Mickael
    Todorov, Milen
    Warin, Nicolas
    Zink, Florence
    Voshol, Hans
    Zecri, Frederic J.
    Sedrani, Richard C.
    Ostermann, Nils
    Brachmann, Saskia M.
    Cotesta, Simona
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (24) : 16173 - 16203
  • [37] Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
    Macaya, Irati
    Roman, Marta
    Welch, Connor
    Entrialgo-Cadierno, Rodrigo
    Salmon, Marina
    Santos, Alba
    Feliu, Iker
    Kovalski, Joanna
    Lopez, Ines
    Rodriguez-Remirez, Maria
    Palomino-Echeverria, Sara
    Lonfgren, Shane M.
    Ferrero, Macarena
    Calabuig, Silvia
    Ludwig, Iziar A.
    Lara-Astiaso, David
    Jantus-Lewintre, Eloisa
    Guruceaga, Elizabeth
    Narayanan, Shruthi
    Ponz-Sarvise, Mariano
    Pineda-Lucena, Antonio
    Lecanda, Fernando
    Ruggero, Davide
    Khatri, Purvesh
    Santamaria, Enrique
    Fernandez-Irigoyen, Joaquin
    Ferrer, Irene
    Paz-Ares, Luis
    Drosten, Matthias
    Barbacid, Mariano
    Gil-Bazo, Ignacio
    Vicent, Silve
    [J]. NATURE COMMUNICATIONS, 2023, 14 (01)
  • [38] Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States
    Zhu, Ya-Ning
    Tang, Meng
    Sun, Ke-Xin
    Gao, Bei
    Shi, Xian-Peng
    Zhang, Peng
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [39] A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101)
    Hong, David S.
    Yaeger, Rona
    Kuboki, Yasutoshi
    Masuishi, Toshiki
    Barve, Minal A.
    Falchook, Gerald Steven
    Govindan, Ramaswamy
    Sohal, Davendra
    Kasi, Pashtoon Murtaza
    Burns, Timothy F.
    Langer, Corey J.
    Puri, Sonam
    Chan, Emily
    Jafarinasabian, Pegah
    Ngarmchamnanrith, Gataree
    Rehn, Marko
    Tran, Qui
    Gandara, David R.
    Strickler, John H.
    Fakih, Marwan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [40] First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation
    De, Surya K.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2024, 31 (03) : 266 - 272
12345